Literature DB >> 19375522

Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.

Shweta Bansal1, David Badesch, Todd Bull, Robert W Schrier.   

Abstract

Much has been learned about the pathophysiological state that underlies the development of increased total body volume and edema in left ventricular failure. Very little, however, is known about the mechanism underlying systemic hypervolemia in patients with isolated right ventricular dysfunction. In this manuscript, we describe our randomized clinical trial to assess the relationship between severity of pulmonary arterial hypertension and neurohormonal activation, total plasma volume and renal function. We assess the role of aldosterone and vasopressin in volume retention in patients with pulmonary arterial hypertension with right ventricular failure. As understanding of the pathogenesis of left ventricular failure has been associated with improved therapies, the better understanding of the mechanisms of isolated right ventricular cardiac failure will also lead to improved patient care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375522      PMCID: PMC2728149          DOI: 10.1016/j.cct.2009.04.003

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  29 in total

1.  Reflex changes in hindlimb and renal vascular resistance in response to distention of the isolated pulmonary arteries of the dog.

Authors:  J R Ledsome; W O Kan
Journal:  Circ Res       Date:  1977-01       Impact factor: 17.367

2.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

Authors:  Mihai Gheorghiade; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Barry H Greenberg; Christopher M O'Connor; Lilin She; Clyde W Yancy; James Young; Gregg C Fonarow
Journal:  Eur Heart J       Date:  2007-02-19       Impact factor: 29.983

Review 3.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

Authors:  Robert W Schrier
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

4.  Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.

Authors:  J Hensen; W T Abraham; J A Dürr; R W Schrier
Journal:  Am J Nephrol       Date:  1991       Impact factor: 3.754

5.  Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.

Authors:  Paul R Forfia; Stephen C Mathai; Micah R Fisher; Traci Housten-Harris; Anna R Hemnes; Hunter C Champion; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

Review 6.  Decreased effective blood volume in edematous disorders: what does this mean?

Authors:  Robert W Schrier
Journal:  J Am Soc Nephrol       Date:  2007-06-13       Impact factor: 10.121

7.  A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.

Authors:  A Gatta; P Angeli; L Caregaro; F Menon; D Sacerdoti; C Merkel
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

8.  Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders.

Authors:  J P Koepke; G F DiBona
Journal:  Am J Physiol       Date:  1987-05

9.  Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.

Authors:  R M Pérez-Ayuso; V Arroyo; R Planas; J Gaya; F Bory; A Rimola; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

10.  Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

Authors:  A A van Vliet; A J Donker; J J Nauta; F W Verheugt
Journal:  Am J Cardiol       Date:  1993-01-21       Impact factor: 2.778

View more
  2 in total

1.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

2.  Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).

Authors:  Bradley A Maron; Aaron B Waxman; Alexander R Opotowsky; Hunter Gillies; Christiana Blair; Reza Aghamohammadzadeh; Joseph Loscalzo; Jane A Leopold
Journal:  Am J Cardiol       Date:  2013-06-07       Impact factor: 2.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.